Related Experiment Video

Updated: Oct 30, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.6K

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer

Kyu Sic You1,2, Yong Weon Yi3, Jeonghee Cho3

  • 1Department of Biochemistry, College of Medicine, Dankook University, Cheonan 31116, Chungcheongnam-do, Korea.

Pharmaceuticals (Basel, Switzerland)
|July 2, 2021
PubMed

Insights

Triple-negative breast cancer (TNBC) lacks effective treatments. Combining epidermal growth factor receptor inhibitors (EGFRis) with other therapies may overcome resistance and offer new options for TNBC patients.

Area of Science:

  • Oncology
  • Medical Research
  • Pharmacology

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic targets.
  • High epidermal growth factor receptor (EGFR) expression correlates with poor prognosis in TNBC.
  • Current anti-EGFR therapies show limited efficacy in TNBC due to intrinsic resistance.

Purpose of the Study:

  • To review existing literature on combination strategies for TNBC treatment.
  • To explore the potential of combining EGFR inhibitors (EGFRis) with other therapeutic agents.
  • To identify promising therapeutic options for overcoming TNBC resistance to EGFRis.

Main Methods:

  • Literature review of studies combining EGFRis with targeted therapeutics or chemotherapeutics.
  • Analysis of clinical and preclinical data on the efficacy of combination strategies.
  • Synthesis of current knowledge on TNBC treatment resistance mechanisms.

Main Results:

  • Combination strategies involving EGFRis show promise in overcoming TNBC resistance.
  • Various combinations with molecularly targeted drugs and conventional chemotherapeutics are under investigation.
  • Evidence suggests potential benefits of combined approaches in preclinical and clinical settings.

Conclusions:

  • Combination therapy represents a promising strategy to improve TNBC treatment outcomes.
  • Further research into optimized combination regimens is warranted.
  • Targeting EGFR in combination holds potential for developing novel therapeutic options for TNBC.
Keywords:
EGFR inhibitor (EGFRi)EGFRi resistanceanti-EGFR therapyanticancercombination therapyepidermal growth factor receptor (EGFR)triple-negative breast cancer (TNBC)

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.0K
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.4K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.9K